P1101 (Ropeginterferon alfa-2b)

About PharmaEssentia

Founded in 2003 by Taiwanese-American executives and scientists, PharmaEssentia has grown from a small startup in Taipei's Nangang Software Park into a publicly traded global biopharmaceutical company (TWSE: 6446). The company operates world-class cGMP biologics facilities and has established a strong international presence with subsidiaries across the US, Europe, Japan, and Asia. PharmaEssentia's innovative approach to redesigning interferon therapies has resulted in breakthrough treatments for rare blood cancers, with BESREMi® representing a paradigm shift in MPN treatment. The company continues to expand its pipeline and global reach while maintaining its commitment to transforming treatment paradigms for patients with serious hematologic diseases.

Therapeutic Areas

Other Various indications Drugs